In addition to these, pathologically proven intestinal metastasis-related GIP has been reported in lenvatinib-treated patients, namely, anaplastic thyroid cancer and hepatocellular carcinoma [64]. This evidence concerns the gene GIP and hepatocellular carcinoma.